Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Change in Receivables (2019 - 2024)

Historic Change in Receivables for Revolution Medicines (RVMD) over the last 6 years, with Q1 2024 value amounting to -$1.3 million.

  • Revolution Medicines' Change in Receivables fell 8495.58% to -$1.3 million in Q1 2024 from the same period last year, while for Dec 2024 it was -$1.3 million, marking a year-over-year increase of 6332.26%. This contributed to the annual value of -$1.3 million for FY2024, which is 6332.26% up from last year.
  • As of Q1 2024, Revolution Medicines' Change in Receivables stood at -$1.3 million, which was down 8495.58% from $945000.0 recorded in Q4 2023.
  • Over the past 5 years, Revolution Medicines' Change in Receivables peaked at $2.0 million during Q3 2020, and registered a low of -$2.9 million during Q4 2020.
  • In the last 5 years, Revolution Medicines' Change in Receivables had a median value of -$678000.0 in 2023 and averaged -$513941.2.
  • Data for Revolution Medicines' Change in Receivables shows a peak YoY increase of 297500.0% (in 2020) and a maximum YoY decrease of 126431.92% (in 2020) over the last 5 years.
  • Revolution Medicines' Change in Receivables (Quarter) stood at -$2.9 million in 2020, then surged by 48.97% to -$1.5 million in 2021, then surged by 82.0% to -$267000.0 in 2022, then skyrocketed by 453.93% to $945000.0 in 2023, then plummeted by 232.7% to -$1.3 million in 2024.
  • Its Change in Receivables stands at -$1.3 million for Q1 2024, versus $945000.0 for Q4 2023 and -$2.2 million for Q3 2023.